J. Goldman & Co’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,456
| Closed | -$78.5K | – | 204 |
|
|
2023
Q3 | $78.5K | Sell |
11,456
-79,483
| -87% | -$544K | ﹤0.01% | 214 |
|
|
2023
Q2 | $943K | Buy |
+90,939
| New | +$943K | 0.03% | 169 |
|
|
2021
Q4 | – | Sell |
-177,740
| Closed | -$3.2M | – | 241 |
|
|
2021
Q3 | $3.2M | Buy |
177,740
+138,651
| +355% | +$2.5M | 0.16% | 108 |
|
|
2021
Q2 | $686K | Sell |
39,089
-105,898
| -73% | -$1.86M | 0.03% | 247 |
|
|
2021
Q1 | $3.65M | Buy |
144,987
+99,911
| +222% | +$2.52M | 0.12% | 131 |
|
|
2020
Q4 | $292K | Sell |
45,076
-351,424
| -89% | -$2.28M | 0.01% | 240 |
|
|
2020
Q3 | $1.02M | Buy |
+396,500
| New | +$1.02M | 0.07% | 155 |
|
|
2017
Q3 | – | Sell |
-60,975
| Closed | -$1.65M | – | 210 |
|
|
2017
Q2 | $1.65M | Buy |
60,975
+12,100
| +25% | +$328K | 0.09% | 114 |
|
|
2017
Q1 | $1.46M | Buy |
48,875
+6,702
| +16% | +$200K | 0.07% | 134 |
|
|
2016
Q4 | $1.15M | Buy |
+42,173
| New | +$1.15M | 0.08% | 128 |
|